# A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

> **NCT02998476** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 60 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Parsaclisib

## Key facts

- **NCT ID:** NCT02998476
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-02
- **Primary completion:** 2019-02-22
- **Final completion:** 2021-02-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02998476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02998476, "A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02998476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*